Drug-associated skin lesions in a patient with myelofibrosis receiving ruxolitinib.
Dermatol Online J
; 20(10)2014 Oct 15.
Article
in En
| MEDLINE
| ID: mdl-25526003
Ruxolitinib, a small molecule JAK-1/2 inhibitor, was approved by the U.S. Food and Drug Administration (FDA) in November 2011, as the first therapeutic for the treatment of intermediate and high-risk myelofibrosis. The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of the most well-studied intracellular signaling networks. Recent advances in our understanding of the complexities of signal activation and regulation of gene expression has provided opportunities for targeted therapeutic interventions. Although numerous inhibitors of the JAK/STAT pathway are currently being evaluated in clinical trials, ruxolitinib represents the first FDA approved in-class JAK inhibitor. We report a drug eruption associated with ruxolitinib.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyrazoles
/
Drug Eruptions
/
Erythema
/
Janus Kinases
/
Primary Myelofibrosis
Type of study:
Risk_factors_studies
Limits:
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Dermatol Online J
Year:
2014
Document type:
Article